Launch Planning

Challenge: Our client was a publicly-traded clinical-stage biopharmaceutical company using an epigenetic approach modulate gene expression in tumor and immune cells to treat cancer. Their lead...

Challenge: Our client was a clinical-stage biotech in the process of early stage planning for the launch of its first drug, a small molecule treatment for a rare endocrine disorder. However, the...

Challenge: A European immune-oncology biotech with a proprietary platform had generated a broad and deep pipeline of oncology assets, which had demonstrated an advantage due to their ability to...

Challenge: Alacrita was engaged by a biopharma company developing a therapeutic for a severe orphan disorder. With Breakthrough status designation from the FDA and a Prime designation from the EMA,...